Scholarlink

<p>Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system–embedded digital tools, and emerging artificial intelligence–enabled methods. We assess the relative strengths and limitations of large language model–based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A unified framework for pre-screening and screening tools in oncology clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月30日

查看全文
  • Denis Horgan,
  • Joseph N. Paulson,
  • Arturo Loaiza-Bonilla,
  • Christer Svedman,
  • Umberto Malapelle,
  • Frédérique Penault-Llorca,
  • Hadi Mohamad Abu Rahsheed,
  • Paul Hofman,
  • Stan Kachnowski,
  • Daniel Schneider,
  • Vivek Subbiah

摘要

Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system–embedded digital tools, and emerging artificial intelligence–enabled methods. We assess the relative strengths and limitations of large language model–based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.